Viridian Therapeutics Inc. (VRDN) just caught the attention of William Blair analysts, who think the company's experimental thyroid eye disease treatment could carve out meaningful market share from Amgen Inc.'s (AMGN) blockbuster Tepezza.

The setup here is interesting. Tepezza pulls in about $2 billion annually in the U.S., but it's only reaching single-digit penetration of the moderate-to-severe thyroid eye disease market. That's the rare autoimmune disorder that causes inflammation and swelling around the eyes, leading to pain and vision problems that can seriously disrupt patients' lives.

Why Viridian's Drug Looks Promising

Analyst Lachlan Hanbury-Brown argues that Viridian's anti-IGF-1R franchise represents a meaningful advance over Tepezza. The key selling point? Convenience and potentially better tolerability.

Veligrotug, Viridian's lead candidate, requires just five infusions compared to Tepezza's eight. Each infusion takes 30-45 minutes instead of 60-90 minutes. That's a significant time savings for patients already dealing with a challenging condition. The lower overall dose might also offer an improved safety profile, and early data suggests the drug works faster.

William Blair acknowledges that growth in the U.S. thyroid eye disease market has plateaued recently. But the firm believes new therapies offering more convenient administration, a cleaner adverse event profile, and benefits for chronic disease patients could actually expand the market beyond its current boundaries.

The Road to Approval

Viridian submitted a marketing application to the FDA in November for veligrotug, including a request for Priority Review. If the agency grants that designation, it could accelerate the timeline toward a potential mid-2026 commercial launch.

But here's where it gets even more interesting: William Blair says the bigger value driver might actually be VRDN-003, a subcutaneous version that patients could self-administer at home using a low-volume autoinjector. Top-line Phase 3 data for that candidate are expected in the first and second quarters of 2026, with an FDA submission planned for year-end 2026.

A home-administered option would be a game-changer compared to the current infusion-center model for Tepezza.

Market Opportunity

The analyst's Outperform rating comes with a fair value estimate of $47 per share. Hanbury-Brown wrote that veligrotug's advantages over Tepezza could drive both share capture from the incumbent and modest market expansion following approval.

With Tepezza barely scratching the surface of its addressable market despite $2 billion in sales, there's clearly room for multiple players. The question is whether Viridian can execute on its clinical and regulatory timelines while demonstrating that its convenience and safety advantages translate into real commercial traction.

Price Action: VRDN stock climbed 3.84% to $31.60 on Wednesday.